Meeting Banner
Abstract #0905

Quantitative deltaT1 (qDT1) as a Replacement for Adjudicated Central ReaderAnalysis: A Sub-Analysis of the RTOG 0625/ACRIN 6677 Multi-Center Brain Tumor Trial

Kathleen M. Schmainda1, Melissa A. Prah2, Zheng Zhang3, Bradley Snyder3, Scott D. Rand4, Todd Jensen5, Daniel P. Barboriak6, and Jerrold L. Boxerman7

1Biophysics, Medical College of Wisconsin, Milwaukee, WI, United States, 2Medical College of Wisconsin, Milwaukee, WI, United States, 3Brown University School of Public Health, Providence, RI, United States, 4Radiology, Medical College of Wisconsin, Milwaukee, WI, United States, 5Jensen Informatics LLC, Brookfield, WI, United States, 6Duke University Medical Center, Durham, NC, United States, 7Rhode Island Hospital & Alpert Medical School of Brown University, Providence, RI, United States

A semi-automatic method for delineating contrast-agent enhancing brain tumor, called quantitative delta T1 (qDT1), was compared to central reader analysis of clinical trial data. The qDT1 method demonstrated equivalence with expert reads for determination of early tumor progression and proved superior for further distinguishing responders from non-responders/non-progressors at the week 8 time point. Using qDT1 provides a solution to the high percentage of intra- and inter-observer disagreements, while being easier to use and more reliable for the daily clinical assessment of tumor response to therapy, as well as for large scale clinical trials.

This abstract and the presentation materials are available to members only; a login is required.

Join Here